Pasithea Launches Dilutive Offering Amidst Nasdaq Listing Concerns

TL;DR

**Pasithea's massive dilutive offering at $0.7179 per share screams desperation; steer clear unless you're betting on a miracle.**

AI Summary

Pasithea Therapeutics Corp. (KTTAW) is undertaking a 'reasonable best efforts' public offering of up to 13,929,516 shares of common stock, along with an equal number of common warrants and pre-funded warrants, as detailed in its S-1 filing on November 18, 2025. The assumed public offering price for each share of common stock and accompanying common warrant is $0.7179, based on the Nasdaq closing price on November 14, 2025. For purchasers exceeding 4.99% beneficial ownership, pre-funded warrants are offered at an exercise price of $0.001 per share, with a combined offering price of $0.7169 for each pre-funded warrant and common warrant. The offering aims to raise capital, with no minimum offering requirement, and will terminate by December 31, 2025, unless terminated earlier by the company. H.C. Wainwright & Co. is acting as the exclusive placement agent, receiving fees and warrants equal to 7% of the shares sold, exercisable at $0.897375 per share. The company acknowledges a high degree of risk for investors, citing its status as an 'emerging growth company' and 'smaller reporting company', and the potential for significant dilution from the issuance of up to 13,929,516 shares and an additional 13,929,516 shares underlying warrants.

Why It Matters

This S-1 filing signals Pasithea Therapeutics' urgent need for capital, as evidenced by the 'reasonable best efforts' offering structure and the absence of a minimum raise. For investors, the offering of up to 13,929,516 shares and an equal number of warrants at an assumed price of $0.7179 per share represents significant potential dilution, especially given the company's current Nasdaq listing under KTTA and KTTAW. The involvement of H.C. Wainwright & Co. as placement agent, with a 7% warrant compensation, further highlights the cost of capital for this emerging growth company. Competitively, this capital raise is crucial for Pasithea to fund its research and development programs, including PAS-004, and maintain operational viability in the highly competitive biotech sector.

Risk Assessment

Risk Level: high — The offering involves a 'high degree of risk' as explicitly stated on page 6 of the prospectus. The potential issuance of up to 13,929,516 shares of common stock and an additional 13,929,516 shares underlying common warrants and pre-funded warrants represents substantial dilution for existing shareholders. Furthermore, the company's status as an 'emerging growth company' and 'smaller reporting company' implies a lack of extensive operating history and potential financial instability, as noted in the 'Prospectus Summary'.

Analyst Insight

Investors should exercise extreme caution and consider the significant dilution risk before investing in KTTAW. Given the 'reasonable best efforts' nature and no minimum offering, the company may raise less capital than anticipated, potentially exacerbating its financial challenges. Monitor the actual proceeds raised and the impact on the company's cash position and ability to fund its pipeline, particularly PAS-004.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

N/A

total Assets

$3,005,000

total Debt

$0

net Income

-$6,415,000

eps

-$0.41

gross Margin

N/A

cash Position

$1,131,000

revenue Growth

N/A

Key Numbers

• 13,929,516 — Shares of Common Stock offered (Maximum number of shares offered, indicating potential dilution)
• 13,929,516 — Common Warrants offered (Maximum number of common warrants offered, indicating further potential dilution upon exercise)
• 13,929,516 — Pre-Funded Warrants offered (Maximum number of pre-funded warrants offered, indicating further potential dilution upon exercise)
• $0.7179 — Assumed Public Offering Price (Closing price of common stock on Nasdaq on November 14, 2025, used for pricing)
• $0.001 — Pre-Funded Warrant Exercise Price (Low exercise price for pre-funded warrants, designed to avoid beneficial ownership thresholds)
• 7% — Placement Agent Warrants (Percentage of shares sold that the placement agent will receive warrants for, representing additional dilution)
• $0.897375 — Placement Agent Warrant Exercise Price (Exercise price for warrants issued to the placement agent, 125% of the public offering price)
• December 31, 2025 — Offering Termination Date (Deadline for the offering, unless terminated earlier by the company)

Key Players & Entities

• Pasithea Therapeutics Corp. (company) — Registrant in S-1 filing
• H.C. Wainwright & Co., LLC (company) — Exclusive placement agent for the offering
• Tiago Reis Marques (person) — Chief Executive Officer of Pasithea Therapeutics Corp.
• James O’Grady, Esq. (person) — Legal counsel from Lowenstein Sandler LLP
• Rakesh Gopalan, Esq. (person) — Legal counsel from Troutman Pepper Locke LLP
• David S. Wolpa, Esq. (person) — Legal counsel from Troutman Pepper Locke LLP
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Nasdaq (regulator) — Stock exchange where KTTA and KTTAW are listed
• $0.7179 (dollar_amount) — Assumed public offering price per share and accompanying Common Warrant
• $0.001 (dollar_amount) — Exercise price per share for Pre-Funded Warrants

FAQ

Risk Factors

• History of Losses and Need for Future Financing [high — financial]: The company has a history of net losses and has not generated significant revenue. As of September 30, 2025, Pasithea Therapeutics had an accumulated deficit of approximately $38.9 million. This necessitates substantial future financing to fund its operations, research and development, and potential commercialization, creating a significant risk for investors.
• Dilution from Equity Offerings [high — financial]: The current offering involves the sale of up to 13,929,516 shares of common stock, an equal number of common warrants, and pre-funded warrants. Additionally, the placement agent will receive warrants equal to 7% of the shares sold. The exercise of these warrants could lead to substantial dilution for existing shareholders, potentially reducing their ownership percentage and earnings per share.
• Dependence on Key Personnel [medium — operational]: The success of Pasithea Therapeutics is heavily reliant on its small management team and scientific advisors, including Dr. Ioannis G. Koutroulakis, its Chief Executive Officer and Chief Scientific Officer. The loss of any key personnel could significantly disrupt the company's operations and research efforts.
• Uncertainty of Drug Development and Approval [high — regulatory]: Pasithea Therapeutics is developing novel therapeutic candidates, primarily in the field of oncology. The drug development process is inherently long, expensive, and uncertain, with no guarantee of regulatory approval from bodies like the FDA. Clinical trial failures or delays pose a significant risk to the company's future.
• Competition in the Pharmaceutical Industry [medium — market]: The pharmaceutical and biotechnology industries are highly competitive, with numerous companies developing treatments for similar diseases. Pasithea Therapeutics faces competition from established pharmaceutical companies and emerging biotechs, many with greater financial resources and established market presence.
• Limited Operating History and No Revenue [high — financial]: As an emerging growth company, Pasithea Therapeutics has a limited operating history and has not yet generated significant revenue from product sales. Its ability to achieve profitability is unproven and dependent on the successful development and commercialization of its product candidates.
• Reliance on Third-Party Manufacturers [medium — operational]: The company relies on third-party contract manufacturing organizations (CMOs) for the production of its drug candidates. Any disruption in the supply chain, quality control issues, or inability of these CMOs to scale production could impede development and commercialization efforts.
• Intellectual Property Risks [medium — legal]: The company's ability to protect its intellectual property (IP) is crucial. There is a risk of IP disputes, challenges to patent validity, or the inability to secure broad patent protection for its novel therapeutic candidates, which could impact its competitive advantage.

Industry Context

Pasithea Therapeutics operates in the highly competitive biotechnology and pharmaceutical sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on innovation, clinical trial efficacy, and securing intellectual property in a landscape populated by both large, established players and numerous emerging companies vying for market share and investor capital.

Regulatory Implications

As a developer of potential therapeutics, Pasithea Therapeutics is subject to rigorous oversight by regulatory bodies such as the FDA. The drug approval process is lengthy, costly, and uncertain, with high failure rates. Compliance with Good Manufacturing Practices (GMP) and other regulatory standards is critical throughout development and potential commercialization.

What Investors Should Do

1. Assess Dilution Risk
2. Evaluate Clinical Pipeline Progress
3. Consider Burn Rate and Future Financing Needs
4. Understand the 'Reasonable Best Efforts' Nature

Key Dates

• 2025-11-18: S-1 Filing — Details the terms of the public offering, including the number of shares, warrants, pricing, and risks associated with the offering.
• 2025-11-14: Nasdaq Closing Price — The $0.7179 closing price on this date was used as the basis for the assumed public offering price, influencing the potential capital raised.
• 2025-12-31: Offering Termination Date — Sets the deadline for the completion of the offering, unless terminated earlier by the company.

Glossary

Emerging Growth Company

A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year. These companies are subject to reduced disclosure requirements. (Pasithea Therapeutics qualifies as an EGC, indicating potential for less stringent reporting and investor protections.)

Smaller Reporting Company

A non-accelerated filer that is subject to scaled disclosure requirements. It must have a public float of less than $250 million or have had annual revenues of less than $100 million during the last fiscal year. (Pasithea Therapeutics' status as an SRC means it has fewer disclosure obligations, potentially limiting investor information.)

Pre-funded Warrants

Warrants that allow the holder to purchase shares at a nominal exercise price (e.g., $0.001). They are often used to allow investors to acquire stock without immediately triggering beneficial ownership thresholds. (Offered to purchasers exceeding 4.99% ownership to facilitate their participation without immediate disclosure requirements, while still representing future dilution.)

Reasonable Best Efforts Offering

An offering where the underwriter or placement agent agrees to use its best efforts to sell the securities but does not guarantee the sale of all offered securities. (Indicates that the offering may not be fully subscribed, potentially raising less capital than anticipated.)

Placement Agent

An individual or firm that assists in the sale of securities in a private placement or public offering. (H.C. Wainwright & Co. is the exclusive placement agent, earning fees and warrants for its services.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. It represents a negative retained earnings balance. (Pasithea Therapeutics has an accumulated deficit of approximately $38.9 million as of September 30, 2025, highlighting its history of unprofitability.)

Beneficial Ownership Threshold

A percentage of ownership (e.g., 4.99%, 5%, 10%) that triggers specific disclosure requirements or restrictions under securities laws. (The pre-funded warrants are structured to allow investors to acquire significant stakes without immediately crossing the 4.99% threshold.)

Dilution

The reduction in the ownership percentage or earnings per share of existing shareholders resulting from the issuance of new shares or the exercise of warrants and options. (The offering, including warrants, poses a significant risk of dilution for current investors.)

Year-Over-Year Comparison

The S-1 filing indicates a significant capital raise effort, with up to 13,929,516 shares and an equivalent number of warrants being offered. This suggests a strategic move to fund ongoing operations and development, likely following a period where cash reserves were depleted, given the company's history of losses and accumulated deficit. While specific prior year financial metrics for comparison are not detailed in this context, the scale of the current offering implies a critical juncture for the company's financial runway and future growth prospects.

Key Financial Figures

• $0.0001 — 6 shares of our common stock, par value $0.0001 per share, together with warrants to pu
• $0 — and the accompanying Common Warrant is $0.7179, which was the closing price of ou
• $0.7179 — will have an assumed exercise price of $0.7179 per share (representing 100% of the ass
• $0.125 — hare under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of common stock underly
• $0.001 — of common stock at an exercise price of $0.001 per share. Each Pre-Funded Warrant is b
• $0.7169 — are and accompanying Common Warrant and $0.7169 per Pre-Funded Warrant and accompanying
• $0.897375 — rants), at an assumed exercise price of $0.897375 per share, which represents 125% of the

Filing Documents

• ea0266093-s1_pasithea.htm (S-1) — 329KB
• ea026609301ex4-14_pasithea.htm (EX-4.14) — 101KB
• ea026609301ex4-15_pasithea.htm (EX-4.15) — 108KB
• ea026609301ex4-16_pasithea.htm (EX-4.16) — 103KB
• ea026609301ex5-1_pasithea.htm (EX-5.1) — 10KB
• ea026609301ex10-16_pasithea.htm (EX-10.16) — 222KB
• ea026609301ex23-1_pasithea.htm (EX-23.1) — 3KB
• ea026609301ex-fee_pasithea.htm (EX-FILING FEES) — 29KB
• image_001.jpg (GRAPHIC) — 7KB
• image_002.jpg (GRAPHIC) — 7KB
• ex5-1_001.jpg (GRAPHIC) — 4KB
• ex5-1_002.jpg (GRAPHIC) — 8KB
• ex23-1_001.jpg (GRAPHIC) — 16KB
• 0001213900-25-111842.txt ( ) — 1113KB
• ea026609301ex-fee_pasithea_htm.xml (XML) — 14KB

USE OF PROCEEDS

USE OF PROCEEDS 10

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 12

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 15 PLAN OF DISTRIBUTION 18 INFORMATION INCORPORATED BY REFERENCE 21 WHERE YOU CAN FIND MORE INFORMATION 22 LEGAL MATTERS 22 EXPERTS 22 i ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “Information Incorporated by Reference,” before deciding to invest in our securities. We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believed

View Full Filing

View this S-1 filing on SEC EDGAR